Patent application number | Description | Published |
20120089606 | GROUPING IDENTITY RECORDS TO GENERATE CANDIDATE LISTS TO USE IN AN ENTITY AND RELATIONSHIP RESOLUTION PROCESS - Provided are a method, system, and computer program product for grouping identity records to generate candidate lists to use in an entity and relationship resolution process. A plurality of identity records are received, wherein the identity records provide attributes of entities, wherein the identity records may provide different or same values for the attributes. The received identity records are grouped into a group of identity records. A composite query on values for selected attributes of the identity records in the group is generated and applied to an entity database to obtain composite results of entity records in the entity database matching the attribute values of the composite query. For the identity records in the group, an individual query on attributes of one of the identity records is performed against the composite results of the entity records to determine a candidate list of entity records from the entity database for the identity record. For the identity records in the group, resolution rules are applied to determine entity records in the determined candidate list that are related one of the identity records in the group according to the resolution rules. Entity relationship information on the determined entity records that are related to the identity records is stored. | 04-12-2012 |
20120215772 | GROUPING IDENTITY RECORDS TO GENERATE CANDIDATE LISTS TO USE IN AN ENTITY AND RELATIONSHIP RESOLUTION PROCESS - Provided is a method for grouping identity records to generate candidate lists to use in an entity and relationship resolution process. A plurality of identity records provide attributes of entities. The received identity records are grouped into a group of identity records. A composite query on values for selected attributes of the identity records in the group is generated and applied to an entity database to obtain composite results of entity records in the entity database matching the attribute values of the composite query. For the identity records in the group, an individual query on attributes of one of the identity records is performed against the composite results of the entity records to determine a candidate list of entity records from the entity database for the identity record. | 08-23-2012 |
20130282726 | GROUPING IDENTITY RECORDS TO GENERATE CANDIDATE LISTS TO USE IN AN ENTITY AND RELATIONSHIP RESOLUTION PROCESS - Provided are a method, system, and computer program product for determining entity relationship information for identity records to add to an entity database. For each selected identity record of a plurality of identity records, an individual query on selected attribute values of the selected identity record is applied against at least one set of entity records to determine a candidate list of the entity records in the at least one set determined to be related to the selected identity record based on the selected attribute values of the selected identity record. Entity relationship information on entity records from the candidate list that are determined to be related to the selected identity record are stored in the entity database. | 10-24-2013 |
Patent application number | Description | Published |
20080275009 | ORAL ADMINISTRATION OF N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-1,3-THIAZOLE-5-CARBOXAMIDE AND SALTS THEREOF - Disclosed are a method of treating cancer and/or other proliferative diseases comprising orally administering N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof, and pharmaceutical compositions comprising N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide or a salt thereof. Also disclosed are N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-1,3-thiazole-5-carboxamide salts, as well as crystalline forms thereof. | 11-06-2008 |
20100105743 | Pharmaceutical compositions and methods for stabilizing the same - Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis. | 04-29-2010 |
20100113534 | Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same - A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1. | 05-06-2010 |
20110046063 | READY-TO-USE BIVALIRUDIN COMPOSITIONS - Ready-to-use bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use bivalirudin compositions. The ready-to-use bivalirudin compositions comprise bivalirudin and one or more stabilizing agents. The one or more stabilizing agents may be buffering agents having a pKa of about 2.5 to about 6.5, pH-adjusting agents, polymers, preservatives, antioxidants, sugars or polyols, or a combination thereof. The ready-to-use bivalirudin compositions may also comprise [9-10]-cycloimido bivalirudin, [11-12]-cycloimido bivalirudin, or a combination thereof. The method of using the ready-to-use bivalirudin compositions comprises administering the ready-to-use compositions to a patient in need thereof. Further, the method of preparing the ready-to-use bivalirudin compositions comprises mixing bivalirudin with one or more stabilizing agents. | 02-24-2011 |
20120088804 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS - Pharmaceutical formulations comprising clevidipine and an antimicrobial agent exhibit a reduced propensity for microbial growth and provide increased convenience to health care workers administering clevidipine-containing formulations to patients. | 04-12-2012 |
20120149770 | Antimicrobial Preservation of Propofol Emulsions - The invention provides intravenous formulations of propofol in an oil-in-water emulsion, having a combination of preservatives. | 06-14-2012 |
20120322835 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME - A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1. | 12-20-2012 |
20120322836 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR STABILIZING THE SAME - Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis. | 12-20-2012 |
20130122093 | FORMULATIONS OF A SRC/ABL INHIBITOR - The invention relates to pharmaceutical compositions of ′N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, and to methods of using the pharmaceutical compositions in the treatment of oncological and immunological disorders | 05-16-2013 |
20130158079 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS - Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities. | 06-20-2013 |
20140005233 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME | 01-02-2014 |
20150018394 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS - Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities. | 01-15-2015 |